Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (NASDAQ: CORT), Gartner, Inc. (NYSE: IT), REGENXBIO Inc. (NASDAQ: RGNX), and Graphic Packaging Holding Company (NYSE: GPK)

NEW YORK CITY, NY / ACCESS Newswire / July 7, 2026 / Lifshitz Law Firm

Corcept Therapeutics, Inc. (NASDAQ:CORT)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the strength of the clinical trials supporting relacorilant by representing them as "powerful support" for Corcept's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"); (ii) the Company falsely conveyed confidence in relacorilant's regulatory prospects by claiming they had communicated with the FDA, foresaw no impediments to approval, and repeatedly told investors that "relacorilant is approaching approval," when, in fact, the FDA had repeatedly raised concerns regarding the adequacy of the clinical evidence supporting the NDA; and (iii) as a result of the foregoing, the Company failed to disclose the known and material risk that Corcept's relacorilant NDA would not be approved.

If you are a CORT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Gartner, Inc. (NYSE:IT)

On February 3, 2026, Gartner issued a press release that announced the Company reported results for the fourth quarter of 2025 and provided its financial outlook for the full year 2026. Additionally, Gene Hall, Gartner's Chairman and Chief Executive Officer, commented, "Fourth quarter financial results were ahead of expectations. We repurchased $2 billion of Gartner stock in 2025. Over the past few months, we increased our leverage through the successful completion of our first investment-grade bond issuance, we entered into a definitive agreement to divest the Digital Markets business, and the Board appointed two new directors who bring unique and valuable skills. Looking ahead, we expect CV to accelerate throughout 2026."

According to Gartner's 8-K, filed on February 3, 2026, "On January 29, 2026, the Company's Board of Directors authorized incremental share repurchases of up to an additional $500.0 million of Gartner's common stock. This authorization is in addition to the previously authorized repurchases of up to $7.0 billion, which, as of the end of December 2025, had approximately $750 million remaining."

On February 3, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are an IT investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

REGENXBIO Inc. (NASDAQ:RGNX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) REGENXBIO's representations concerning its plan to develop and commercialize RGX‑111, a one‑time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, were materially misleading; (ii) the Company's positive statements regarding the anticipated success of RGX‑111's Phase I/II clinical trial, purportedly supported by continuing favorable biomarker and safety data, lacked a reasonable basis; and (iii) the efficacy and safety profile of RGX‑111 was materially overstated.

If you are an RGNX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Graphic Packaging Holding Company (NYSE:GPK)

On February 3, 2026, the Company issued a press release reporting its fourth quarter and full year 2025 results. As highlighted in the release: (i) Net Income in fourth quarter 2025 was $71 million, or $0.24 per diluted share, versus $138 million, or $0.46 per diluted share in fourth quarter 2024. Fourth quarter 2025 and 2024 Net Income were impacted by a net charge from non-recurring and special items and amortization of purchased intangibles of $14 million and $41 million, respectively. Excluding non-recurring and special items and amortization of purchased intangibles, Adjusted Net Income for the fourth quarter of 2025 was $85 million, or $0.29 per diluted share, and $179 million, or $0.59 per diluted share in fourth quarter 2024; and (ii) Net Income for full-year 2025 was $444 million, or $1.48 per diluted share, versus $658 million, or $2.16 per diluted share for full-year 2024. Full-year 2025 and 2024 Net Income were impacted by a net charge from non-recurring and special items and amortization of purchased intangibles of $95 million and $101 million, respectively. Excluding non-recurring and special items and amortization of purchased intangibles, Adjusted Net Income for full-year 2025 was $539 million, or $1.80 per diluted share, and $759 million, or $2.49 per diluted share for full-year 2024.

Additionally, Robbert Rietbroek, the Company's President and CEO stated, "Consumer affordability created a challenging market for our customers and competitive pressure remains a near-term headwind. As we move into 2026, our priorities are clear: drive operational excellence; deliver exceptional customer service; improve our cost structure; and drive substantial free cash flow to strengthen the balance sheet and return capital to shareholders. I have initiated a comprehensive review of our organization structure, operations, and footprint, and a selective review of our portfolio to ensure that our resources are focused where we can create the greatest value for our shareholders."

On February 3, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are a GPK investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC

Phone: 516-493-9780

|Facsimile: 516-280-7376

Email: [email protected]

SOURCE: Lifshitz Law Firm